363 related articles for article (PubMed ID: 21552099)
1. Optimizing the administration of fixed-dose rate gemcitabine plus capecitabine using an alternating-week schedule: a dose finding and early efficacy study in advanced pancreatic and biliary carcinomas.
Ko AH; Espinoza AM; Jones KA; Venook AP; Bergsland EK; Kelley RK; Dito E; Ong A; Hanover CS; Coakley FV; Tempero MA
Am J Clin Oncol; 2012 Oct; 35(5):411-7. PubMed ID: 21552099
[TBL] [Abstract][Full Text] [Related]
2. A phase I trial of nab-paclitaxel, gemcitabine, and capecitabine for metastatic pancreatic cancer.
Ko AH; Truong TG; Kantoff E; Jones KA; Dito E; Ong A; Tempero MA
Cancer Chemother Pharmacol; 2012 Dec; 70(6):875-81. PubMed ID: 23053263
[TBL] [Abstract][Full Text] [Related]
3. Capecitabine combined with gemcitabine (CapGem) as first-line treatment in patients with advanced/metastatic biliary tract carcinoma.
Cho JY; Paik YH; Chang YS; Lee SJ; Lee DK; Song SY; Chung JB; Park MS; Yu JS; Yoon DS
Cancer; 2005 Dec; 104(12):2753-8. PubMed ID: 16294346
[TBL] [Abstract][Full Text] [Related]
4. A phase II trial of fixed-dose rate gemcitabine plus capecitabine in metastatic/advanced biliary tract cancer patients.
Santini D; Virzi V; Vasile E; Vincenzi B; Catalano V; Graziano F; Masi G; Bronte G; Russo A; Falcone A; Tonini G
Oncology; 2012; 82(2):75-82. PubMed ID: 22327844
[TBL] [Abstract][Full Text] [Related]
5. Dose finding and early efficacy study of gemcitabine plus capecitabine in combination with bevacizumab plus erlotinib in advanced pancreatic cancer.
Starling N; Watkins D; Cunningham D; Thomas J; Webb J; Brown G; Thomas K; Oates J; Chau I
J Clin Oncol; 2009 Nov; 27(33):5499-505. PubMed ID: 19858399
[TBL] [Abstract][Full Text] [Related]
6. Phase I trial of vandetanib in combination with gemcitabine and capecitabine in patients with advanced solid tumors with an expanded cohort in pancreatic and biliary cancers.
Kessler ER; Eckhardt SG; Pitts TM; Bradshaw-Pierce EL; O'byrant CL; Messersmith WA; Nallapreddy S; Weekes C; Spratlin J; Lieu CH; Kane MA; Eppers S; Freas E; Leong S
Invest New Drugs; 2016 Apr; 34(2):176-83. PubMed ID: 26715573
[TBL] [Abstract][Full Text] [Related]
7. A Phase II Study of Biweekly Cisplatin, Fixed-Dose-Rate Gemcitabine and Infusional 5-Fluorouracil in Patients With Metastatic Pancreatic and Biliary Cancers.
Davis EJ; Griffith KA; Kim EJ; Ruch JM; McDonnell KJ; Zalupski MM
Am J Clin Oncol; 2018 Feb; 41(2):128-132. PubMed ID: 26535993
[TBL] [Abstract][Full Text] [Related]
8. Phase I study of biweekly oxaliplatin, gemcitabine and capecitabine in patients with advanced upper gastrointestinal malignancies.
Tan BR; Brenner WS; Picus J; Marsh S; Gao F; Fournier C; Fracasso PM; James J; Yen-Revollo JL; McLeod HL
Ann Oncol; 2008 Oct; 19(10):1742-8. PubMed ID: 18534963
[TBL] [Abstract][Full Text] [Related]
9. A phase I study of sorafenib, oxaliplatin and 2 days of high dose capecitabine in advanced pancreatic and biliary tract cancer: a Wisconsin oncology network study.
LoConte NK; Holen KD; Schelman WR; Mulkerin DL; Deming DA; Hernan HR; Traynor AM; Goggins T; Groteluschen D; Oettel K; Robinson E; Lubner SJ
Invest New Drugs; 2013 Aug; 31(4):943-8. PubMed ID: 23263993
[TBL] [Abstract][Full Text] [Related]
10. Capecitabine plus oxaliplatin (CapOx) versus capecitabine plus gemcitabine (CapGem) versus gemcitabine plus oxaliplatin (mGemOx): final results of a multicenter randomized phase II trial in advanced pancreatic cancer.
Boeck S; Hoehler T; Seipelt G; Mahlberg R; Wein A; Hochhaus A; Boeck HP; Schmid B; Kettner E; Stauch M; Lordick F; Ko Y; Geissler M; Schoppmeyer K; Kojouharoff G; Golf A; Neugebauer S; Heinemann V
Ann Oncol; 2008 Feb; 19(2):340-7. PubMed ID: 17962204
[TBL] [Abstract][Full Text] [Related]
11. Dose-escalation study of fixed-dose rate gemcitabine combined with capecitabine in advanced solid malignancies.
Attia S; Morgan-Meadows S; Holen KD; Bailey HH; Eickhoff JC; Schelman WR; Traynor AM; Mulkerin DL; Campbell TC; McFarland TA; Huie MS; Cleary JF; Tevaarwerk AJ; Alberti DB; Wilding G; Liu G
Cancer Chemother Pharmacol; 2009 Jun; 64(1):45-51. PubMed ID: 18841362
[TBL] [Abstract][Full Text] [Related]
12. Second-line treatment with a combination of continuous 5-fluorouracil, doxorubicin, and mitomycin-C (conti-FAM) in gemcitabine-pretreated pancreatic and biliary tract cancer.
Lee S; Oh SY; Kim BG; Kwon HC; Kim SH; Rho MH; Kim YH; Rho MS; Jeong JS; Kim HJ
Am J Clin Oncol; 2009 Aug; 32(4):348-52. PubMed ID: 19363436
[TBL] [Abstract][Full Text] [Related]
13. Combining capecitabine and gemcitabine in patients with advanced pancreatic carcinoma: a phase I/II trial.
Hess V; Salzberg M; Borner M; Morant R; Roth AD; Ludwig C; Herrmann R
J Clin Oncol; 2003 Jan; 21(1):66-8. PubMed ID: 12506172
[TBL] [Abstract][Full Text] [Related]
14. Patient-reported outcomes of patients with advanced biliary tract cancers receiving gemcitabine plus capecitabine: a multicenter, phase II trial of the Swiss Group for Clinical Cancer Research.
Koeberle D; Saletti P; Borner M; Gerber D; Dietrich D; Caspar CB; Mingrone W; Beretta K; Strasser F; Ruhstaller T; Mora O; Herrmann R;
J Clin Oncol; 2008 Aug; 26(22):3702-8. PubMed ID: 18669455
[TBL] [Abstract][Full Text] [Related]
15. A Phase Ib Study of the FGFR/VEGFR Inhibitor Dovitinib With Gemcitabine and Capecitabine in Advanced Solid Tumor and Pancreatic Cancer Patients.
Ma WW; Xie H; Fetterly G; Pitzonka L; Whitworth A; LeVea C; Wilton J; Mantione K; Schihl S; Dy GK; Boland P; Iyer R; Tan W; Brady W; Straubinger RM; Adjei AA
Am J Clin Oncol; 2019 Feb; 42(2):184-189. PubMed ID: 30418178
[TBL] [Abstract][Full Text] [Related]
16. A phase I trial of sorafenib plus gemcitabine and capecitabine for patients with advanced renal cell carcinoma: New York Cancer Consortium Trial NCI 6981.
Tagawa ST; Milowsky MI; Jeske S; Mazumdar M; Kung S; Sung M; Lehrer D; Matulich D; Selzer J; Wright JJ; Nanus DM
Am J Clin Oncol; 2011 Oct; 34(5):443-8. PubMed ID: 20881475
[TBL] [Abstract][Full Text] [Related]
17. A phase 1 study of fixed dose rate gemcitabine and irinotecan in patients with advanced pancreatic and biliary cancer.
Sun W; Hewitt MR; Theobald MR; Hershock D; Haller DG
Cancer; 2007 Dec; 110(12):2768-74. PubMed ID: 17932893
[TBL] [Abstract][Full Text] [Related]
18. Biweekly high-dose gemcitabine alone or in combination with capecitabine in patients with metastatic pancreatic adenocarcinoma: a randomized phase II trial.
Scheithauer W; Schüll B; Ulrich-Pur H; Schmid K; Raderer M; Haider K; Kwasny W; Depisch D; Schneeweiss B; Lang F; Kornek GV
Ann Oncol; 2003 Jan; 14(1):97-104. PubMed ID: 12488300
[TBL] [Abstract][Full Text] [Related]
19. Gemcitabine-based chemotherapy for advanced biliary tract carcinomas.
Abdel-Rahman O; Elsayed Z; Elhalawani H
Cochrane Database Syst Rev; 2018 Apr; 4(4):CD011746. PubMed ID: 29624208
[TBL] [Abstract][Full Text] [Related]
20. A phase I study of the biomodulation of capecitabine by docetaxel and gemcitabine (mGTX) in previously untreated patients with metastatic adenocarcinoma of the pancreas.
Hill ME; Li X; Kim S; Campbell A; Culler K; Bloomston M; Zalupski M; Hejna G; Bekaii-Saab T
Cancer Chemother Pharmacol; 2011 Mar; 67(3):511-7. PubMed ID: 20461379
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]